他汀类药物对脑卒中预防作用的Meta分析

被引：4

作者：

白海星 ^{[1
]}

张剑宇 ^{[2
]}

机构：

[1] 山西医科大学

[2] 山西医科大学第二医院

来源：

中西医结合心脑血管病杂志 | 2010年 / 8卷 / 07期

关键词：

全因死亡; Meta分析; 他汀类药物; 脑卒中;

D O I：

暂无

中图分类号：

R743.3 [急性脑血管疾病（中风）];

学科分类号：

1002 ;

摘要：

目的系统评价他汀类药物对脑卒中的防治。方法检索7个数据库和已发表系统评价的参考文献,提取与全因死亡率、脑卒中发病率和胆固醇水平变化的相关数据。使用随机或固定效应模型汇总数据,进行Meta回归分析。结果纳入31项试验(n=128427)评价他汀类药物对脑卒中的预防作用,结果显示相对危险度(RR)为0.84[95%置信区间(CI)0.79～0.89]。其中28项试验评价全因死亡率RR0.91,95%CI[0.88,0.95],11项评价心血管死亡事件(RR0.89),7项评价缺血性脑血管事件(RR0.80),7项报告出血性脑卒中(RR0.83),15项报告致命性脑卒中(RR0.84)。只有一项试验报告他汀类药物用于二级预防(RR0.85)。结论他汀类药物治疗对全因死亡和缺血性脑卒中提供高水平的保护作用。对于有主要血管事件的高危人群,需考虑延长他汀类药物的治疗,但对有出血风险的患者应慎用。

引用

页码：806 / 808

页数：3

共 17 条

[1] Cerebrovascular Events in Renal Transplant Recipients [J].

Abedini, Sadollah ;

Holme, Ingar ;

Fellstrom, Bengt ;

Jardine, Alan ;

Cole, Edward ;

Maes, Bart ;

Holdaas, Hallvard .

TRANSPLANTATION, 2009, 87 (01) :112-117

[2]

Primary prevention of cardiovascular disease with pravastatin in Japan （MEGA Study）: a prospective randomised controlled trial[J] . Haruo Nakamura,Kikuo Arakawa,Hiroshige Itakura,Akira Kitabatake,Yoshio Goto,Takayoshi Toyota,Noriaki Nakaya,Shoji Nishimoto,Masaharu Muranaka,Akira Yamamoto,Kyoichi Mizuno,Yasuo Ohashi.The Lancet . 2006 (9542)

[3] Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (Treating to New Targets) study [J].

Waters, David D. ;

LaRosa, John C. ;

Barter, Philip ;

Fruchart, Jean-Charles ;

Gotto, Antonio M., Jr. ;

Carter, Roddy ;

Breazna, Andrei ;

Kastelein, John J. P. ;

Grundy, Scott M. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (09) :1793-1799

[4]

The Role of Statins in Preventing Stroke[J] . Nenad Trubelja,Carl Vaughan,Neil L. Coplan.Preventive Cardiology . 2005 (2)

[5]

Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: A randomized study with intravascular ultrasound[J] . Anna Sonia Petronio,Giovanni Amoroso,Ugo Limbruno,Barbara Papini,Marco De Carlo,Andrea Micheli,Nicola Ciabatti,Mario Mariani.American Heart Journal . 2005 (3)

[6]

Effect of Intensive Lipid Lowering, With or Without Antioxidant Vitamins, Compared With Moderate Lipid Lowering on Myocardial Ischemia in Patients With Stable Coronary Artery Disease: The Vascular Basis for the Treatment of Myocardial Ischemia Study[J] . Peter H. Stone,Donald M. Lloyd-Jones,Scott Kinlay,Balz Frei,William Carlson,Joel Rubenstein,Thomas C. Andrews,Michael Johnstone,George Sopko,Holly Cole,John Orav,Andrew P. Selwyn,Mark A. Creager.Circulation . 2005 (14)

[7]

Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of PHYLLIS—A Randomized Double-Blind Trial[J] . Alberto Zanchetti,Gaetano Crepaldi,M Gene Bond,Giuseppe Gallus,Fabrizio Veglia,Giuseppe Mancia,Alessandro Ventura,Giovannella Baggio,Lorena Sampieri,Paolo Rubba,Giovanni Sperti,Alberto Magni.Stroke . 2004 (12)

[8] Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria [J].

Asselbergs, FW ;

Diercks, GFH ;

Hillege, HL ;

van Boven, AJ ;

Janssen, WMT ;

Voors, AA ;

de Zeeuw, D ;

de Jong, PE ;

van Veldhuisen, DJ ;

van Gilst, WH .

CIRCULATION, 2004, 110 (18) :2809-2816

[9]

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study （CARDS）: multicentre randomised placebo-controlled trial[J] . Helen M Colhoun,D John Betteridge,Paul N Durrington,Graham A Hitman,H Andrew W Neil,Shona J Livingstone,Margaret J Thomason,Michael I Mackness,Valentine Charlton-Menys,John H Fuller.The Lancet . 2004 (9435)

[10]

Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics[J] . Michael J. Koren,Donald B. Hunninghake.Journal of the American College of Cardiology . 2004 (9)

← 1 2 →